BREAKING NEWS

Device has shelf life of 12 to 18 months
Glecaprevir/pibrentasvir combo achieves high virologic response rates
Pivotal study meets all secondary endpoints
More than 3,000 cases reported in continental U.S.
Lumacaftor/ivacaftor combination previously approved for patients 12 years of age and older
“Artificial pancreas” adjusts insulin levels
Treatment reduces monthly migraine days

P&T September 2016
Table of Contents

Features

Escalating drug prices have seeded interest in value-based purchasing, but confusion and controversy have slowed the Centers for Medicare and Medicaid Services, state agencies, and private insurers from pursuing the potential savings.
As researchers devise ever-more-costly therapies and P&T committees try to balance innovation and affordability, managed care experts warn that the struggle to pay the bills could threaten the sustainability of the nation’s inefficient health care system.
Health Care & Law
Telehealth is becoming mainstream in the U.S., as more consumers, employers, hospital systems, and even insurers adopt the technology. The authors explore the challenges of regulation, reimbursement, and licensing as the modality evolves.
Meeting Highlights
We present sessions on the latest trials and treatments for colorectal cancer from the ESMO World Congress and report on new developments in diagnostics and therapy presented at the European Post-Chicago Melanoma/Skin Cancer Meeting.

Departments

Medication Errors
Improve staff training with vendor partnerships
Prescription: Washington
Congress set to tackle biosimilar naming debate
New Drugs/Drug News
Approvals, new indications, regulatory activities, and more
Cabozantinib (Cabometyx) for advanced renal cell carcinoma; glycopyrrolate/formoterol fumarate (Bevespi Aerosphere) for chronic obstructive pulmonary disease; and ephedrine sulfate (Akovaz) for hypotension during anesthesia
Drug Forecast
Aripiprazole lauroxil (Aristada) for the treatment of schizophrenia

P&T TV

Regorafenib Safe for Older Colorectal Cancer Patients

Eric Van Cutsem, MD, discusses a subgroup analysis involving patients 75 years of age and older in the Consign study of regorafenib for treatment-refractory metastatic colorectal cancer. The analysis found no major differences in safety compared with younger patients as long as the patients were fit enough to be eligible for treatment—so age itself is no reason to withhold regorafenib.

ESMO World Congress on Gastrointestinal Cancer, June 29–July 2, 2016